AAAAAA
Results: 1-25/53
Authors:
Thompson, IM
Tangen, CM
Tolcher, A
Crawford, ED
Eisenberger, M
Moinpour, CM
Citation: Im. Thompson et al., Association of African-American ethnic background with survival in men with metastatic prostate cancer, J NAT CANC, 93(3), 2001, pp. 219-225
Authors:
Thompson, IM
Tangen, CM
Tolcher, A
Crawford, ED
Eisenberger, M
Moinpour, CM
Citation: Im. Thompson et al., Re: Association of African-American ethnic background with survival in menwith metastatic prostate cancer - Response, J NAT CANC, 93(15), 2001, pp. 1175-1175
Authors:
Schroder, LE
Lew, D
Flanigan, RC
Eisenberger, MA
Seay, TE
Hammond, N
Needles, BM
Crawford, ED
Citation: Le. Schroder et al., Phase II evaluation of suramin in advanced renal cell carcinoma - A Southwest Oncology Group study, UROL ONCOL, 6(4), 2001, pp. 145-148
Authors:
Pienta, KJ
Fisher, EI
Eisenberger, MA
Mills, GM
Goodwin, JW
Jones, JA
Dakhil, SR
Crawford, ED
Hussain, MHA
Citation: Kj. Pienta et al., A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology GroupTrial (SWOG 9407), PROSTATE, 46(4), 2001, pp. 257-261
Authors:
Gelmann, EP
Chia, D
Pinsky, PF
Andriole, GL
Crawford, ED
Reding, D
Hayes, RB
Kramer, BS
Woodrum, DL
Gohagan, JK
Levin, DL
Citation: Ep. Gelmann et al., Relationship of demographic and clinical factors to free and total prostate-specific antigen, UROLOGY, 58(4), 2001, pp. 561-566
Authors:
Crawford, ED
Citation: Ed. Crawford, Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression - Editorial comment, UROLOGY, 58(2), 2001, pp. 150-151
Authors:
Kucuk, O
Fisher, E
Moinpour, CM
Coleman, D
Hussain, MHA
Sartor, AO
Chatta, GS
Lowe, BA
Eisenberger, MA
Crawford, ED
Citation: O. Kucuk et al., Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG 9235), UROLOGY, 58(1), 2001, pp. 53-58
Authors:
Schmitt, B
Wilt, TJ
Schellhammer, PF
DeMasi, V
Sartor, O
Crawford, ED
Bennett, CL
Citation: B. Schmitt et al., Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review, UROLOGY, 57(4), 2001, pp. 727-732
Authors:
Batuello, JT
Gamito, EJ
Crawford, ED
Han, M
Partin, AW
McLeod, DG
O'Donnell, C
Citation: Jt. Batuello et al., Artificial neural network model for the assessment of lymph node spread inpatients with clinically localized prostate cancer, UROLOGY, 57(3), 2001, pp. 481-485
Authors:
Flanigan, RC
Salmon, SE
Blumenstein, BA
Bearman, SI
Roy, V
McGrath, PC
Caton, JR
Munshi, N
Crawford, ED
Citation: Rc. Flanigan et al., Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N ENG J MED, 345(23), 2001, pp. 1655-1659
Authors:
Hussain, MHA
Glass, TR
Forman, J
Sakr, W
Smith, DC
Al-Sarraf, M
Jones, J
Balcerzak, SP
Crawford, ED
Grossman, HB
Citation: Mha. Hussain et al., Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: A Southwest Oncology Group study, J UROL, 165(1), 2001, pp. 56-60
Authors:
Campbell, T
Blasko, J
Crawford, ED
Forman, J
Hanks, G
Kuban, D
Montie, J
Moul, J
Pollack, A
Raghavan, D
Ray, P
Roach, M
Steinberg, G
Stone, N
Thompson, I
Vogelzang, N
Vijayakumar, S
Citation: T. Campbell et al., Clinical staging of prostate cancer: Reproducibility and clarification of issues, INT J CANC, 96(3), 2001, pp. 198-209
Authors:
Ziada, AM
Lisle, TC
Snow, PB
Levine, RF
Miller, G
Crawford, ED
Citation: Am. Ziada et al., Impact of different variables on the outcome of patients with clinically confined prostate carcinoma - Prediction of pathologic stage and biochemicalfailure using an artificial neural network, CANCER, 91(8), 2001, pp. 1653-1660
Authors:
Abouelfadel, Z
Crawford, ED
Citation: Z. Abouelfadel et Ed. Crawford, Experience of prostate cancer awareness week, CURR CLIN U, 2001, pp. 239-254
Authors:
Crawford, ED
Citation: Ed. Crawford, The Costabile article reviewed, ONCOLOGY-NY, 14(2), 2000, pp. 204-205
Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed
Authors:
Crawford, ED
Citation: Ed. Crawford, Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed, ONCOLOGY-NY, 14(12), 2000, pp. 1688
Authors:
Suh, CI
Shanafelt, T
May, DJ
Shroyer, KR
Bobak, JB
Crawford, ED
Miller, GJ
Markham, N
Glode, LM
Citation: Ci. Suh et al., Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer, MOL CELL PR, 14(4), 2000, pp. 211-217
Authors:
Hussain, M
Fisher, EI
Petrylak, DP
O'Connor, J
Wood, DP
Small, EJ
Eisenberger, MA
Crawford, ED
Citation: M. Hussain et al., Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study, J CL ONCOL, 18(5), 2000, pp. 1043-1049
Authors:
Small, EJ
Lew, D
Redman, BG
Petrylak, DP
Hammond, N
Gross, HM
Eastham, JA
Crawford, ED
Citation: Ej. Small et al., Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trialend point, J CL ONCOL, 18(13), 2000, pp. 2537-2544
Authors:
White, RWD
Deitch, AD
Daneshmand, S
Blumenstein, B
Lowe, BA
Sagalowsky, AI
Smith, JA
Schellhammer, PF
Stanisic, TH
Grossman, HB
Messing, E
Crissman, JD
Crawford, ED
Citation: Rwd. White et al., The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer - A Southwest Oncology Group Study, EUR UROL, 37(5), 2000, pp. 595-600
Authors:
Prorok, PC
Andriole, GL
Bresalier, RS
Buys, SS
Chia, D
Crawford, ED
Fogel, R
Gelmann, EP
Gilbert, F
Hasson, MA
Hayes, RB
Johnson, CC
Mandel, JS
Oberman, A
O'Brien, B
Oken, MM
Rafla, S
Reding, D
Rutt, W
Weissfeld, JL
Yokochi, L
Gohagan, JK
Citation: Pc. Prorok et al., Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, CONTR CL TR, 21(6), 2000, pp. 273S-309S
Authors:
Dalesio, O
van Tinteren, H
Clarke, M
Peto, R
Schroder, FH
Dechering, I
Evans, V
Godwin, J
Blumenstein, BA
Crawford, ED
Denis, L
Hall, R
Hill, C
Iversen, P
Shipley, WU
Soloway, M
Sylvester, R
Citation: O. Dalesio et al., Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, LANCET, 355(9214), 2000, pp. 1491-1498
Authors:
Vessella, RL
Lange, PH
Partin, AW
Chan, DW
Sokoll, LJ
Sasse, EA
Crawford, ED
Citation: Rl. Vessella et al., Probability of prostate cancer detection based on results of a multicenterstudy using the AxSYM free PSA and total PSA assays, UROLOGY, 55(6), 2000, pp. 909-914
Authors:
Crawford, ED
Citation: Ed. Crawford, Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality - Editorial comment, UROLOGY, 55(3), 2000, pp. 332-332
Authors:
Crawford, ED
Citation: Ed. Crawford, Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: Prognostic factors and generalizability of a multicenter trial to clinical practice - Comment, J UROL, 163(5), 2000, pp. 1485-1485